Citations

Clear

2303 citation(s) found for "Yu, Edward".

Agency in physiological dynamics
Rogers, James R. , Gallaher, Edward J., Dingli, David

Mayo Clinic

System Dynamics Review | June 23, 2022 | Volume: 38 | Issue: 2 | Pages: 169-189

10.1002/sdr.1713 Get It

AbstractWith a view to finding new applications of biomedical system dynamics, this article expands upon on our talk at the 2021 International System Dynamics Conference on the occasion of receiving the J. W. Forrester Award for the article, “Personalized ESA doses for anemia management in hemodialysis patients with end‐stage renal disease” (System Dynamics Review 2018, 34(1–2): 121–153). We summarize the evolution of a project which took place in a clinical setting between 2008 and 2015 that led to the award‐winning article. We present concepts from receptor theory that informed the first system dynamics application of biophysical system dynamics to the successful diagnosis, prescription, administration, and improvement of individualized patient care. We expand upon these ideas to present a generalized structure, DART (Dynamic Approach to Receptor Theory). It can be used to simulate the physiological effects of any agent, be it an exogenous pharmacological agent, an endogenous enzyme or hormone, or a toxin of some sort. We suggest including within the pharmacological technical literature easily acquired but frequently omitted critical parameter values and rate constants. These would enable researchers to perform transient analyses of biophysical phenomena in addition to static equilibrium analyses typically performed. With the availability of this data, we suggest that the fundamental tools of system dynamics might be used to reconceptualize the 100‐year‐old field of “occupation theory” (today, receptor theory) to deliver high‐resolution insights into physiological dynamics and the preventive, prescriptive, and palliative interventions they might require. It is our hope that these ideas could pave the way forward to novel, groundbreaking applications in biomedical system dynamics. © 2022 System Dynamics Society.
Recent Use of Non–Vitamin K Antagonist Oral Anticoagulants and Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase
Brown, Caitlin S. , Webb, Andrew , Rech, Megan A.

Mayo Clinic

JAMA | June 21, 2022 | Volume: 327 | Issue: 23 | Pages: 2354

10.1001/jama.2022.6350 | PMID 35727284 Get It

Delayed recurrence of pediatric arteriovenous malformations after radiologically confirmed obliteration
Oushy, Soliman , Gilder, Hannah E., Pollock, Bruce E. , Ahn, Edward S. , Oushy, Soliman H , Nesvick, Cody L. , Lanzino, Giuseppe , Daniels, David J.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | June 20, 2022 | Volume: 30 | Issue: 2 | Pages: 195-202

10.3171/2022.4.peds21471 | PMID 35623369 Get It

OBJECTIVE Arteriovenous malformations (AVMs) are a major cause of intracerebral hemorrhage in children, resulting in significant morbidity and mortality. Moreover, the rate of AVM recurrence in children is significantly higher than in adults. The aim of this study was to define the risk of delayed pediatric AVM (pAVM) recurrence following confirmed radiological obliteration. Further understanding of this risk could inform the role of long-term radiological surveillance. METHODS The authors conducted a retrospective review of ruptured and unruptured pAVM cases treated at a single tertiary care referral center between 1994 and 2019. Demographics, clinical characteristics, treatment modalities, and AVM recurrence were analyzed. RESULTS A total of 102 pediatric patients with intracranial AVMs, including 52 (51%) ruptured cases, were identified. The mean patient age at presentation was 11.2 ± 4.4 years, and 51 (50%) patients were female. The mean nidus size was 2.66 ± 1.44 cm. The most common Spetzler-Martin grades were III (32%) and II (31%). Stereotactic radiosurgery was performed in 69.6% of patients. AVM obliteration was radiologically confirmed in 68 (72.3%) of 94 patients with follow-up imaging, on angiography in 50 (73.5%) patients and on magnetic resonance imaging in 18 (26.5%). AVM recurrence was identified in 1 (2.3%) of 43 patients with long-term surveillance imaging over a mean follow-up of 54.7 ± 38.9 months (range 2–153 months). This recurrence was identified in a boy who had presented with a ruptured AVM and had been surgically treated at 5 years of age. The AVM recurred 54 months after confirmed obliteration on surveillance digital subtraction angiography. Two other cases of presumed AVM recurrence following resection in young children were excluded from recurrence analysis because of incomplete sets of imaging available for review. CONCLUSIONS AVM recurrence following confirmed obliteration on imaging is a rare phenomenon, though it occurs more frequently in the pediatric population. Regular long-term follow-up with dedicated surveillance angiography is recommended even after obliteration following resection.
P28 Effect of endoscopic disease criteria on endoscopic outcomes in the SEAVUE study
Allez, Matthieu , Lewis, James D. , Gasink, Chrispher, Hoops, Tim, Izanec, James , Scherl, Ellen , Pannacione, Remo, Sandborn, William J. , Lewis, James D , Hanauer, Stephen B. , Danese, Silvio , Irving, Peter Miles , Gasink, Christopher , Hoops, Timothy, Ma, Tony, Loftus, Edward V. , Sands, Bruce E

Mayo Clinic

Poster presentations | June 20, 2022 | Volume: No volume available | Issue: No issue available | Pages: A50-A52

10.1136/gutjnl-2022-bsg.90 Get It

O30 Closure of perianal fistula in patients receiving ustekinumab in the SEAVUE and STARDUST trials
Laurent, Peyrin-Biroulet, Gasink, Christopher , Hoops, Timothy, Izanec, James , Nazar, Maciej, Bravatà, Ivana, Lahaye, Marjolein, Panaccione, Remo , Ma, Tony Xuyen , Irving, Peter Miles , Loftus, Edward V. , Danese, Silvio , Sands, Bruce E

Mayo Clinic

Oral presentations | June 20, 2022 | Volume: No volume available | Issue: No issue available | Pages: A17-A17

10.1136/gutjnl-2022-bsg.30 Get It

Frontline polatuzumab vedotin for diffuse large B‐cell lymphoma: A survey of clinician impressions
Major, Ajay , Cliff, Edward R. Scheffer , Ermann, Daniel A. , Durani, Urshila , Russler‐Germain, David A. , Major, Ajay , Durani, Urshila , Russler-Germain, David A

Mayo Clinic

eJHaem | June 17, 2022 | Volume: 3 | Issue: 3 | Pages: 930-935

10.1002/jha2.505 | PMID 36051026 Get It

AbstractIn the POLARIX trial, pola‐R‐CHP demonstrated improved progression‐free survival (PFS) compared to R‐CHOP in untreated intermediate‐ to high‐risk DLBCL. We surveyed practicing clinicians regarding their interpretation of POLARIX, including impressions of efficacy, safety, and cost. Of 174 respondents, most from academic centers (82%) in the United States (57%), 70% stated they would not replace R‐CHOP with pola‐R‐CHP due to insufficient PFS difference, lack of overall survival benefit, and excessive cost. Respondents not recommending pola‐R‐CHP expressed concerns about financial implications for both society and patients. We observed considerable heterogeneity in both study interpretation and plans for real‐world implementation of pola‐R‐CHP.
Abstract 705: Inhibition of H3.3 S31 phosphorylation by the pediatric glioma driver mutation, H3.3 K27M, results in chromosomal instability, loss of p53 regulation, and tumorigenesis
Grigore, Florina , Langfald, Alyssa, Day, Charles , Daniels, David J. , Robinson, James, Hinchcliffe, Edward H.

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 705-705

10.1158/1538-7445.am2022-705 Get It

Abstract The heterozygous H3.3 K27M mutation is found in the majority of pediatric High-Grade Glioma’s (pHGG). H3.3 K27M is thought to promote tumor formation through altered epigenetic gene regulation. However, it is unclear if epigenetic reprogramming alone is sufficient for glioma formation. H3.3 contains a unique Serine at position 31 which is phosphorylated in early mitosis (where it functions in chromosome segregation) and again in late M/early G1 when a mitotic error has occurred (triggering p53 expression). We found that pHGG cell lines harboring H3.3 K27M have significantly reduced S31 phosphorylation as compared to both pHGG and non-transformed H3.3 WT cells. When compared to WT H3.3 in an in vitro kinase assay, H3.3 K27M exhibits an ~60% reduction in S31 phosphorylation by Chk1, the mitotic S31 kinase. In normal diploid cells, expression of K27M or non-phosphorylatable S31A mutant significantly increased chromosome missegregation. Yet expressing a phosphomimetic double mutant (K27M/S31E) did not significantly alter the rate of chromosome mis-segregation compared to WT. Furthermore, patient-derived pHGG lines harboring K27M have significantly higher rates of chromosome mis-segregation compared to an H3.3 WT pHGG line or H3.3 WT non-transformed human cells. We used CRISPR gene editing to remove the H3.3 K27M allele or replace it with WT H3.3. In both cases, loss of K27M elevated pS31 levels and reduced chromosome mis-segregations. Yet, when K27M was replaced with S31A, the mis-segregation rate remained similar to the parental K27M cells. In normal cells, chromosome missegregation stimulates p53-dependent cell cycle arrest in G1 to prevent the proliferation of aneuploid daughters. However, cells expressing H3.3 K27M or S31A failed to arrest following missegregation - despite having WT p53. To determine if the induction of chromosomal instability would alter tumor formation, we expressed H3.3 WT, K27M or S31A in combination with PDGFβ in a glioma mouse model. Expression of WT H3.3 failed to generate high-grade tumors. But 66% of mice expressing K27M and 93% of those expressing H3.3 S31A developed diffuse high-grade brain tumors by 100 days. Our results suggest that loss of phospho-S31 alone is oncogenic because H3.3 S31A-expressing cells are WT for K27me3. Our results demonstrate that H3.3 K27M inhibits Ser31 phosphorylation both in vitro and in vivo, leading to both chromosome missegregation and loss of subsequent G1 arrest - thus creating diffuse midline gliomas with both dynamic, complex karyotypes and epigenetic reprogramming. Citation Format: Charles Day, Florina Grigore, Alyssa Langfald, David J. Daniels, James Robinson, Edward Hinchcliffe. Inhibition of H3.3 S31 phosphorylation by the pediatric glioma driver mutation, H3.3 K27M, results in chromosomal instability, loss of p53 regulation, and tumorigenesis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 705.
Abstract 5891: The age-dependent association of risk factors with pancreatic cancer
Kim, Jihye , Wang, Qiao-Li , Babić, Ana , Li, Donghui , Petersen, Gloria M. , Perez, Kimberly , Ng, Kimmie , Giovannucci, Edward L. , Stampfer, Meir J., Wolpin, Brian M. , Yuan, Chen , Lee, Alice A. , Ámundadóttir, Laufey T. , Klein, Alison P. , McCullough, Marjorie L. , Risch, Harvey A. , Stolzenberg‐Solomon, Rachael Z. , Kraft, Peter

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 5891-5891

10.1158/1538-7445.am2022-5891 Get It

Abstract Importance: Pancreatic cancer presents as advanced disease in >80% of patients; yet, appropriate ages to consider prevention and early detection strategies are poorly defined. Objective: To investigate age-specific associations and attributable risks of pancreatic cancer for established modifiable and non-modifiable risk factors. Design, Setting, and Participants: We included 167,483 participants from 2 prospective U.S. cohort studies with 1190 incident cases of pancreatic cancer identified during >30 years of follow-up; 5107 pancreatic cancer cases and 8845 control participants of European ancestry from a completed multicenter genome-wide association study (GWAS); and 248,893 pancreatic cancer cases documented in the U.S. Surveillance, Epidemiology, and End Results (SEER) Program. Exposures: Across different age categories, we investigated cigarette smoking, obesity, diabetes, height, and non-O blood group in the prospective cohorts; weighted polygenic risk score of 22 previously identified single nucleotide polymorphisms in the GWAS; and male sex and Black race in the SEER program. Main outcomes and measures: Risk of developing pancreatic cancer by age evaluated by Cox, logistic, or Poisson regression, as determined by the study design. Results: In the prospective cohorts, all 5 risk factors were more strongly associated with pancreatic cancer risk among younger participants, with associations greatly attenuated among those over 70 years. The HRs comparing participants with 3-5 risk factors to those with no risk factors were 9.24 (95% CI, 4.11-20.77) among those aged ≤60 years, 3.00 (95% CI, 1.85-4.86) among those aged 61-70 years, and 1.46 (95% CI, 1.10-1.94) among those over 70 years (Pheterogeneity = 3×10-5). These factors together were related to 65.6%, 49.7%, and 17.2% of incident pancreatic cancers in these age groups, respectively. In the GWAS, the polygenic risk score was most strongly associated with pancreatic cancer risk among those aged ≤60 years, with lesser associations identified in older participants (Pheterogeneity = .01). In the SEER Program, male sex and Black race were also more strongly associated with pancreatic cancer risk among younger individuals (Pheterogeneity < 1×10-8). Conclusions and relevance: Inherited and lifestyle factors are more strongly associated with earlier-onset pancreatic cancer, emphasizing the importance of age at initiation for cancer prevention and control programs targeting this highly lethal malignancy. Citation Format: Chen Yuan, Jihye Kim, Qiao-Li Wang, Alice A. Lee, Ana Babic, PanScan/PanC4 I-III Consortium, Laufey T. Amundadottir, Alison P. Klein, Donghui Li, Marjorie L. McCullough, Gloria M. Petersen, Harvey A. Risch, Rachael Z. Stolzenberg-Solomon, Kimberly Perez, Kimmie Ng, Edward L. Giovannucci, Meir J. Stampfer, Peter Kraft, Brian M. Wolpin. The age-dependent association of risk factors with pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5891.
Postoperative protocols following endoscopic skull base surgery: An evidence‐based review with recommendations
Abiri, Arash , Patel, Tirth , Nguyen, Emily , Tajudeen, Bobby A. , Schlosser, Rodney J. , Adappa, Nithin D. , Adappa, Nithin D. , Choby, Garret , Wang, Eric W , Kuan, Edward C , Schlosser, Rodney J , Birkenbeuel, Jack L. , Choby, Garret , Adappa, Nithin D.

Mayo Clinic

International Forum of Allergy & Rhinology | June 9, 2022 | Volume: 13 | Issue: 1 | Pages: 42-71

10.1002/alr.23041 | PMID 35678720 Get It

AbstractBackgroundPostoperative management strategies for endoscopic skull base surgery (ESBS) vary widely because of limited evidence‐based guidance.MethodsThe PubMed, EMBASE, and Cochrane databases were systematically reviewed from January 1990 through February 2022 to examine 18 postoperative considerations for ESBS. Nonhuman studies, articles written in a language other than English, and case reports were excluded. Studies were assessed for levels of evidence, and each topic's aggregate grade of evidence was evaluated.ResultsA total of 74 studies reporting on 18 postoperative practices were reviewed. Postoperative pain management, prophylactic antibiotics, and lumbar drain use had the highest grades of evidence (B). The literature currently lacks high quality evidence for a majority of the reviewed ESBS precautions. There were no relevant studies to address postoperative urinary catheter use and medical intracranial pressure reduction.ConclusionThe evidence for postoperative ESBS precautions is heterogeneous, scarce, and generally of low quality. Although this review identified the best evidence available in the literature, it suggests the urgent need for more robust evidence. Therefore, additional high‐quality studies are needed in order to devise optimal postoperative ESBS protocols.
Predictive value of baseline patient-rated treatment bother for early anastrozole discontinuation in a racially diverse cohort: Results from ECOG-ACRIN E1Z11.
Lee, Ju‐Whei , O’Connell, Nathaniel S. , Loprinzi, Charles L. , Flynn, Patrick J. , Gareen, Ilana F. , Carlos, Ruth C. , Smith, Mary Lou , Cella, David , Zhao, Fengmin , Peipert, John Devin , Stearns, Vered , Chang, Victor T. , Jegede, Opeyemi A. , Ip, Edward H. , Graham, Noah , Henry, N. Lynn , Fisch, Michael , Sparano, Joseph A. , Gray, Robert J. , Wagner, Lynne I.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 12094-12094

10.1200/jco.2022.40.16_suppl.12094 Get It

12094 Background: The Functional Assessment of Cancer Therapy patient-reported outcomes (PRO) item GP5 (“I am bothered by side effects of treatment”) estimates treatment tolerability. We aimed to extend our previous finding that GP5 predicts early aromatase inhibitor (AI) discontinuation (E1Z03, 96% White) in the racially diverse E1Z11 trial cohort. Methods: E1Z11 was coordinated by the ECOG-ACRIN NCI Community Oncology Research Program (NCORP) Research Base. Postmenopausal women initiating anastrozole per clinical care for ER+ stage I-III breast cancer with a pain score 0-3/10 and no rheumatologic comorbidities were eligible. Accrual of a racially diverse cohort of 1,000 women, including Black and Asian women, was planned. GP5 was administered prior to initiating anastrozole (trial baseline) and at 3, 6, 9 and 12 months. GP5 was scored on a 5-point Likert scale from 0 (not at all) to 4 (very much) and dichotomized as no/little treatment bother (0/1) or moderate/high treatment bother (2-4), consistent with previous analyses. A univariate Cox proportional hazards model estimated baseline GP5’s association with treatment duration via hazard ratio (HR). Early treatment discontinuation status was defined as treatment duration < 12 months with discontinuation not attributed to disease progression or death (n = 4), consistent with previous analyses. Results: 1,046 women enrolled from 6/2013-10/2018 (640 White, 201 Black, 205 Asian), including 590 (56%) from NCORP Community or Minority/Underserved Sites. Approximately 10% (100/987 with GP5 data) reported moderate/high treatment bother prior to initiating anastrozole. Anastrozole discontinuation rate at 1-year was 26.2% overall; it was lower among women with no/little treatment bother (25.7%, GP5 = 0-1) compared to moderate/high treatment bother prior to initiating anastrozole (34.7%, GP5 = 2-4; HR = 1.50, 95% confidence interval [CI]:1.04-2.15, p = 0.027). Subgroup analyses by racial cohort showed a similar predictive effect of GP5 in the White (n = 606, HR = 1.76, 95% CI: 1.12-2.77, p = 0.014) and Black (n = 184, HR = 1.85, 95% CI: 0.92-3.71, p = 0.079) cohorts, but not in the Asian cohort (n = 197, HR = 0.40, 95% CI: 0.10-1.62, p = 0.20). Conclusions: Moderate/high treatment bother prior to starting anastrozole was observed in 10% of patients and associated with a higher risk of early discontinuation, except in Asian patients. Our findings support the presence of a treatment tolerability threshold which can be compromised by pre-treatment burden. Treatment tolerability may also be influenced by cultural and genetic factors, which will be explored in further analysis of genetic and PRO data. Clinical trial information: NCT01824836.